Erard T, Quéreux G, Amini-Adle M, Montaudié H, Charles J, Puyraveau M, Jeudy G, Bernard P, Grange F, Legoupil D, Zehou O, Celerier P, Lesage C, Khammari A, Aubin F, Nardin C

Eur J Cancer. 2026 06 25;244:116878

Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.

Robert C, Gérard E, Lanoy E, Quéreux G, Bernard P, Viguier M, Grange F, Meyer N, Dinulescu M, Legoupil D, Neidhardt EM, Saiag P, Trabelsi S, Célérier P, Nardin C, Maubec E, Duval-Modeste AB, Hainaut E, Darras S, Maillard H, Guegan S, Arnault JP, Stoebner PE, LE Corre Y, Peuvrel L, Bonniaud B, Herrscher H, Granel-Brocard F, Vataire AL, Tabellion A, Lebbé C, Mortier L

Eur J Cancer. 2026 03 5;238:116596

Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study.

de Givry AC, Manchon P, Veyri M, Delyon J, Malissen N, Gaudy-Marqueste C, Zehou O, Jannic A, Gérard E, Kramkimel N, Longvert C, Maubec E, Boileau M, Stoebner PE, Montaudié H, Quéreux G, L'Orphelin JM, Poirier E, Girard C, Nardin C, Mortier L, Ferré VM, Descamps V, Spano JP, Laouenan C, Ghosn J, Lebbé C, Brunet Possenti F

Oncologist. 2025 12 15;:

Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years.

Ruiz ES, Muñoz-Couselo E, Montaudié H, Berciano-Guerrero MA, de la Gala MDCÁ, Charles J, Quéreux G, Nardin C, Tur RY, Dalle S, Beylot-Barry M, Ladwa R, McGrath M, Brungs D, Harris D, Shue H, Tazbirkova A, Fourie S, Malan DR, Oliviero J, Wilcoxen LN, Gray WG, Clingan P

J Am Acad Dermatol. 2025 09 29;:

Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients.

David C, Coquelle C, Le Corre Y, L'Orphelin JM, Nardin C, Aubin F, Cassecuel J, Dreno B, Wierzbiecka-Hainault E, Bens G, Beneton N, Dinulescu M, Kervarrec T, Saiag P, Blom A, Samimi M

Ann Dermatol Venereol. 2025 08 2;152(3):103411

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).

Nardin C, Cavalieri C, Lebbé C, Gérard E, Puyraveau M, Vergara R, Maubec E, Kramkimel N, Lesage C, Rouanet J, Bonniaud B, Puzenat E, Popescu D, Baroudjian B, Le Corre Y, Saiag P, Brunet Possenti F, Saint-Jean M, Montaudié H, Amini-Adle M, Belkaid S, Grange F, Mansard S, Béjar CL, Darras S, Pages C, Tournier E, Funck-Brentano E, Aubin F

Br J Dermatol. 2025 07 14;:

Brain metastases from Merkel cell carcinoma: A nationwide retrospective study.

Caillot R, Blom A, Lebbé C, Da Meda L, Boileau M, Dutriaux C, Guillon B, Granel-Brocard F, Viguier M, Lesage C, Nardin C, Mansard S, Charpentier C, Zehou O, Gaudy-Marqueste C, Legoupil D, Minart B, Kieny A, Montaudié H, L'orphelin JM, Quéreux G, Le Corre Y, Robert C, Mortier L, Saiag P, Samimi M

Eur J Cancer. 2025 07 10;227:115637

Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD-L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors.

Nardin C, Vautrot V, Naiken I, Doussot A, Puzenat E, De Girval C, Garrido C, Aubin F, Gobbo J

J Extracell Biol. 2025 06;4(6):e70066

Immune checkpoint inhibitors use in lung transplant recipients: a case series and systematic review of literature.

Mahmoud N, Pamart G, Nardin C, Schuller A, Hirschi S, Dégot T, Falcoz PE, Olland A, Tacquard CA, Kessler R, Coiffard B, Renaud-Picard B

ESMO Open. 2025 03 31;10(4):104537

INCREASED RISK OF CUTANEOUS SQUAMOUS CELL CARCINOMAS IN PATIENTS WITH SÉZARY SYNDROME: A NATIONWIDE MULTICENTER RETROSPECTIVE STUDY.

Guillon L, Ram-Wolff C, Boulinguez S, Beylot-Barry M, D'incan M, Adamski H, Faiz S, Le Corre Y, Dalle S, Amatore F, Cornillault A, Chaby G, Duval-Modeste AB, Dalac S, Oro S, Montaudié H, Nardin C, Lenormand C, Maubec E, Stoebner PE, Dereure O,

J Am Acad Dermatol. 2025 03 22;:

TIE-2 expressing monocytic myeloid-derived suppressor cells are involved in resistance to anti-PD-1 therapy mediated by angiopoietin 2 in melanoma patients.

Marguier A, Mathiot J, NDao B, Wespiser M, Pereira V, Lecoester B, Boullerot L, Malfroy M, Laheurte C, Aubin F, Adotevi O, Nardin C

J Invest Dermatol. 2025 03 18;:

Ipilimumab + nivolumab combination or nivolumab monotherapy as first-line treatment in patients with metastatic melanoma: conclusions from a real-world French national cohort.

Nardin C, Vernerey D, Aubin F

Br J Dermatol. 2025 02 27;:

Malignant melanoma arising in a sebaceous naevus leading to the discovery of a pathogenic germline MUTYH mutation: a case report.

Hennemann A, Selmani Z, Perales A, Nardin C, Aubin F

Clin Exp Dermatol. 2025 02 4;:

Multi-organ failure from topical salicylic acid preparation: two cases.

Perales A, Nardin C, Linuson G, Dias J, Moreau J, Dupond AS, Aubin F

Eur J Dermatol. 2025 02 1;35(1):68-69

Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment.

Tzoumpa S, Villette B, Granel-Brocard F, Dutriaux C, Memmi A, Jeudy G, Tafani V, Saint-Jean M, Nardin C, Funck-Brentan E, Corre YL, Quereux G, Maubec E

Immunotherapy. 2024 09 13;:1-9

Vulvar Paget's disease: a population-based cancer registry descriptive study.

Nardin C, Fattet P, Ramanah R, Pretalli JB, Pelletier F, Woronoff AS, Aubin F

J Gynecol Obstet Hum Reprod. 2024 09 1;:102846

Wnt/beta-catenin activated non pilomatrical carcinoma of the skin: a case series.

Kervarrec T, Lei KC, Sohier P, Macagno N, Jullie ML, Frouin E, Goto K, Taniguchi K, Hamard A, Taillandier A, Tallet A, Collin C, Sahin Y, Barry F, Taibjee S, Cokelaere K, Houben R, Schrama D, Nardin C, Aubin F, Doucet L, Pissaloux D, Tirode F, de la Fouchardière A, Balme B, Laurent-Roussel S, Becker JC, von Deimling A, Samimi M, Cribier B, Battistella M, Calonje E, Guyétant S

Mod Pathol. 2024 07 31;:100586

Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée).

Rousset P, Nardin C, Maubec E, Heidelberger V, Picard A, Troin L, Gerard E, Kramkimel N, Steff-Naud M, Quéreux G, Gaudy-Marqueste C, Lesage C, Mignard C, Jeudy G, Jouary T, Saint-Jean M, Baroudjian B, Archier E, Mortier L, Lebbe C, Montaudié H

Oncologist. 2024 07 2;:

Incidence and trends of first basal cell carcinomas in France between 1980 and 2019: a regional population-based registry study.

Hammas K, Nardin C, Boyer S, Michel C, Aubin F, Woronoff AS

Br J Dermatol. 2024 05 15;:

Drug-induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome.

Plaçais M, Laparra A, Maria ATJ, Kramkimel N, Perret A, Manson G, Comont T, Coutte L, Nardin C, Ouali K, Danlos FX, Noël N, Messayke S, Michel M, Lambotte O, Michot JM

Am J Hematol. 2024 04 20;:

Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.

Hennemann A, Puzenat E, Decreuse M, Vuillier F, Nardin C, Aubin F

Melanoma Res. 2024 04 5;:

The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, Boespflug A,

Ann Dermatol Venereol. 2024 02 6;151(1):103243

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.

Spehner L, Orillard E, Falcoz A, Lepiller Q, Bouard A, Almotlak H, Kim S, Curtit E, Meynard G, Jary M, Nardin C, Asgarov K, Abdeljaoued S, Chartral U, Mougey V, Ben Khelil M, Lopez M, Loyon R, Vernerey D, Adotevi O, Borg C, Mansi L, Kroemer M

BMJ Oncol. 2023 12 14;2(1):e000054

Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).

Hazard M, Duval F, Dutriaux C, Beylot-Barry M, Pham-Ledard A, Quereux G, Amini-Adle M, Heidelberger V, Aubin F, Saint-Jean M, Nardin C, Abed S, Leccia MT, Mansard S, Prey S, Khammari A, Dréno B, Gérard E

J Neurol. 2023 12 6;:

Detection of wildtype Merkel cell polyomavirus genomic sequence and VP1 transcription in a subset of Merkel cell carcinoma.

Kervarrec T, Appenzeller S, Tallet A, Jullie ML, Sohier P, Guillonneau F, Rütten A, Berthon P, Le Corre Y, Hainaut-Wierzbicka E, Blom A, Beneton N, Bens G, Nardin C, Aubin F, Dinulescu M, Visée S, Herfs M, Touzé A, Guyétant S, Samimi M, Houben R, Schrama D

Histopathology. 2023 10 13;:

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients.

Reichert C, Baldini C, Mezghani S, Maubec E, Longvert C, Mortier L, Quereux G, Jannic A, Machet L, de Quatrebarbes J, Nardin C, Beneton N, Amini Adle M, Funck-Brentano E, Descamps V, Hachon L, Malissen N, Baroudjian B, Brunet-Possenti F,

Cancers (Basel). 2023 08 30;15(17):

Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).

Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, Jeudy G, Samimi M, Lesage C, Boussemart L, Peuvrel L, Rouanet J, Brunet-Possenti F, Gerard E, Seris A, Jouary T, Saint-Jean M, Puyraveau M, Saiag P, Aubin F

Cancers (Basel). 2023 07 10;15(14):

Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.

Geoffrois L, Harlé A, Sahki N, Sikanja A, Granel-Brocard F, Hervieu A, Mortier L, Jeudy G, Michel C, Nardin C, Huin-Schohn C, Merlin JL

BMC Cancer. 2023 06 16;23(1):554

Impact of adjuvant radiation therapy on survival and recurrence in stages I-III Merkel Cell Carcinoma: a retrospective study of 312 patients.

Pottier C, Marchand A, Kervarrec T, Le Corre Y, Nardin C, Aubin F, Wierzbicka-Hainaut E, Cassecuel J, Dreno B, Bens G, Beneton N, Legoupil D, Dinulescu M, Saiag P, Fily-Blom A, Samimi M

J Am Acad Dermatol. 2023 06 10;:

Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome. A multicentre, retrospective, real-world French study.

Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, Dobos G, Pham-Ledard A, Ram-Wolff C, D'Incan M, Grange F, Braniste V, Bagot M

J Eur Acad Dermatol Venereol. 2023 04 27;:

Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.

Toulemonde E, Chevret S, Battistella M, Neidhardt EM, Nardin C, Le Du F, Meyer N, Véron M, Gambotti L, Lamrani-Ghaouti A, Jamme P, Chaffaut C, De Pontville M, Saada-Bouzid E, Beylot-Barry M, Simon C, Jouary T, Marabelle A, Mortier L

Cancer Immunol Immunother. 2023 04 17;:

Distinct regulation of EZH2 and its repressive H3K27me3 mark in Polyomavirus -positive and -negative Merkel cell carcinoma.

Durand MA, Drouin A, Mouchard A, Durand L, Esnault C, Berthon P, Tallet A, Le Corre Y, Hainaut-Wierzbicka E, Blom A, Saiag P, Beneton N, Bens G, Nardin C, Aubin F, Dinulescu M, Collin C, Fromont-Hankard G, Cribier B, Laurent-Roussel S, Cokelaere K, Houben R, Schrama D, Peixoto P, Hervouet E, Bachiri K, Kantar D, Coyaud E, Guyétant S, Samimi M, Touzé A, Kervarrec T

J Invest Dermatol. 2023 04 8;:

Nivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: A case report and review of the literature.

Neuville C, Aubin F, Puzenat E, Popescu D, Crepin T, Nardin C

Front Oncol. 2022 12 12;12:1032844

Clinical Features, Histological Characteristics, and Disease Outcomes of Mycosis Fungoides in Children and Adolescents: A Nationwide Multicentre Cohort of 46 Patients.

Welfringer-Morin A, Barroil M, Fraitag S, Szablewski V, Boccara O, Lacour JP, Chiaverini C, Bagot M, Ram-Wolff C, Vignon-Pennamen MD, Dalle S, D'incan M, Amatore F, Beylot-Barry M, Vergier B, Mazereeuw-Hautier J, Tedbirt B, Quereux G, Carpentier O, Skowron F, Bertrand Y, Van Eeckhout P, Dekeuleneer V, Nardin C, Adamski H, Ingen-Housz-Oro S, Dereure O, Bodemer C

Dermatology. 2022 11 4;:1-8

Cutaneous vasculitis associated with Mycosis Fungoides.

Nardin C, Lesage C, Goubeau E, Aubriot-Lorton MH, Lacheretz-Szablewski V, Ortonne N, Saizonou I, Aubin F, Dereure O, Dalac-Rat S

J Eur Acad Dermatol Venereol. 2022 10 12;:

An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.

Dutriaux C, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Saiag P

Eur J Cancer. 2022 09 25;175:254-262

Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma.

Hennemann A, Collonge Rame MA, Puzenat E, Ged C, Harbon S, Aubin F, Nardin C

Acta Oncol. 2022 08 11;:1-3

TIE-2 Signaling Activation by Angiopoietin 2 On Myeloid-Derived Suppressor Cells Promotes Melanoma-Specific T-cell Inhibition.

Marguier A, Laheurte C, Lecoester B, Malfroy M, Boullerot L, Renaudin A, Seffar E, Kumar A, Nardin C, Aubin F, Adotevi O

Front Immunol. 2022 07 22;13:932298

Investigation of the RB1-SOX2 axis constitutes a tool for viral status determination and diagnosis in Merkel cell carcinoma.

Thanguturi S, Tallet A, Miquelestorena-Standley E, Coco C, Le Corre Y, Hainaut-Wierzbicka E, Blom A, Saiag P, Beneton N, Bens G, Zaragoza J, Nardin C, Aubin F, Dinulescu M, Machet MC, Houben R, Schrama D, Collin C, Fromont G, Jullie ML, Macagno N, Gaboriaud P, Berthon P, Touzé A, Guyétant S, Samimi M, Kervarrec T

Virchows Arch. 2022 Apr 12;:

PD-L1 in circulating exosomes of Merkel cell carcinoma.

Zanella A, Vautrot V, Aubin F, Avoscan L, Samimi M, Garrido C, Gobbo J, Nardin C

Exp Dermatol. 2022 Jan 7;:

Increase in American Joint Committee on Cancer Stage at Diagnosis for Patients with Skin Cancers after the COVID-19 Lockdown.

Nardin C, Senot L, Pernot P, Puzenat E, Aubin F, Morin L

Acta Derm Venereol. 2021 Nov 29;:

Merkel cell polyomavirus-negative -Merkel cell carcinoma originating from in situ squamous cell carcinoma: a keratinocytic tumor with neuroendocrine differentiation.

Kervarrec T, Appenzeller S, Samimi M, Sarma B, Sarosi EM, Berthon P, Le Corre Y, Hainaut-Wierzbicka E, Blom A, Benethon N, Bens G, Nardin C, Aubin F, Dinulescu M, Jullie ML, Pekár-Lukacs Á, Calonje E, Thanguturi S, Tallet A, Wobser M, Touzé A, Guyétant S, Houben R, Schrama D

J Invest Dermatol. 2021 Sep 1;:

Naturally occurring Telomerase-specific CD4 T cell Immunity in Melanoma.

Nardin C, Laheurte C, Puzenat E, Boullerot L, Ramseyer M, Marguier A, Jacquin M, Godet Y, Aubin F, Adotevi O

J Invest Dermatol. 2021 Aug 2;:

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabraf

Saiag P, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C

Eur J Cancer. 2021 Jul 6;154:57-65

Late-onset adverse events under anti-PD1 therapy in melanoma patients: an observational study from MELBASE, a nationwide prospective cohort.

Carlet C, Dalle S, Leccia MT, Mortier L, Dalac-Rat S, Dutriaux C, Legoupil D, Montaudié H, Dereure O, De Quatrebarbes J, Granel-Brocard F, Le-Bouar M, Charles J, Brunet-Possenti F, Dreno B, Lefevre W, Allayous C, Lebbe C, Nardin C

J Am Acad Dermatol. 2021 Jun 18;:

Cemiplimab-rwlc in Advanced Cutaneous Squamous Cell Carcinoma: a real-life experience in a French Dermatology Department.

Guillaume T, Puzenat E, Popescu D, Aubin F, Nardin C

Br J Dermatol. 2021 Jun 9;:

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.

Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G, Vienot A, Nardin C, Bazan F, Lepiller Q, Westeel V, Adotévi O, Borg C, Kroemer M

Eur J Cancer. 2021 Mar 26;150:1-9

Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: A national multicenter study.

Weill A, Delyon J, Descamps V, Deschamps L, Dinulescu M, Dupuy A, Célérier P, Nardin C, Aubin F, Le Corre Y, Heidelberger V, Maubec E, Malissen N, Longvert C, Machet L, Gounant V, Brosseau S, Bonniaud B, Jeudy G, Psimaras D, Doucet L, Lebbe C, Zalcman G, De Masson A, Baroudjian B, Leonard-Louis S, Hervier B, Brunet-Possenti F,

Rheumatology (Oxford). 2021 Mar 16;:

Primary cutaneous lymphoma: a population-based cancer registry descriptive study of 155 consecutive cases diagnosed between 1979 and 2016.

Fréchet L, Woronoff AS, Gérazime A, Puzenat E, Dupond AS, Nardin C, Popescu D, Aubin F

Leuk Lymphoma. 2021 Mar 8;:1-6

Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series.

Frechet L, Puzenat E, Charollais R, Dresco F, Carlet C, Gallais-Serezal I, Nardin C, Aubin F

Eur J Dermatol. 2021 Mar 1;:

A survey of psoriasis patients on biologics during COVID-19: a high-epidemic area experience - Franche Comté, France.

Gallais-Serezal I, Puzenat E, Moreau J, Dresco F, Pelletier F, Nardin C, Aubin F

Eur J Dermatol. 2021 Feb 12;:

Cutaneous manifestations of COVID-19 in the Franche-Comté region of France: A monocentric study.

Jacquin-Porretaz C, Ducournau A, Dupond AS, Nardin C, Aubin F, Courtieu C,

Ann Dermatol Venereol. 2021 Jan 9;:

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.

Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N

J Immunother Cancer. 2020 Nov;8(2):

Epidemiological changes in cutaneous lymphomas: an analysis of 8,593 patients from the French Cutaneous Lymphoma Registry.

Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, Ingen-Housz-Oro S, Battistella M, D Incan M, Rouanet J, Franck F, Vignon-Pennamen MD, Franck N, Carlotti A, Boulinguez S, Lamant L, Petrella T, Dalac S, Joly P, Courville P, Rivet J, Dereure O, Amatore F, Taix S, Grange F, Durlach A, Quéreux G, Josselin N, Moulonguet I, Mortier L, Dubois R, Maubec E, Laroche L, Michel L, Templier I, Barete S, Nardin C, Augereau O, Vergier B, Bagot M

Br J Dermatol. 2020 Oct 31;:

Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?

Seckler F, Doussot A, Colpart P, Turco C, Calame P, Aubin F, Algros MP, Borg C, Nardin C, Heyd B

J. Hepatol.. 2020 Sep 17;:

COVID-19 and skin cancer management: French nation-wide questionnaire survey from real-life practice.

Nardin C, Puzenat E, Dalac S, Maubec E, Aubin F,

J Dermatolog Treat. 2020 Jul 29;:1-6

MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?

Zanella A, Doussot A, Puzenat E, Aubin F, Nardin C

Melanoma Res.. 2020 Jun 23;:

Angiosarcoma: A population-based cancer registry descriptive study of 45 consecutive cases diagnosed between 1979 and 2016.

Colas M, Gérazime A, Popescu D, Puzenat E, Chaigneau L, Woronoff AS, Dupond AS, Nardin C, Aubin F

Rare Tumors. 2020 ;12:2036361320979216

Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study.

Carlet C, Bichard D, Richard MA, Mahé E, Saillard C, Brenaut E, Dupuy A, Misery L, Villani A, Jullien D, Puzenat E, Nardin C, Aubin F, Groupe de Recherche Sur le Psoriasis de la Société Française de Dermatologie

Dermatol Res Pract. 2020 ;2020:2042636

Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients.

Cordonnier M, Nardin C, Chanteloup G, Derangere V, Algros MP, Arnould L, Garrido C, Aubin F, Gobbo J

J Extracell Vesicles. 2020 ;9(1):1710899

Vitiligo under anti-PD1 therapy is associated with increased survival in melanoma patients.

Nardin C, Jeand'heur A, Bouiller K, Valnet-Rabier MB, Dresco F, Castagna J, Mareschal A, Carlet C, Nerich V, Limat S, Puzenat E, Aubin F

J. Am. Acad. Dermatol.. 2019 Nov 14;:

Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department.

Roche H, Bouiller K, Puzenat E, Deveza E, Roche B, Pelletier F, van de Laak A, Dupond AS, Nardin C, Aubin F

J Dermatolog Treat. 2019 09;30(6):540-544

[Idiopathic granulomatous mastitis associated with erythema nodosum].

Jacquin-Porretaz C, Devalland C, Delapparent T, Nardin C, Dupond AS

Ann Dermatol Venereol. 2019 Sep;146(8-9):571-576

Increased Levels of Interleukin-17A Exosomes in Psoriasis.

Jacquin-Porretaz C, Cordonnier M, Nardin C, Boullerot L, Chanteloup G, Vautrot V, Adotevi O, Garrido C, Gobbo J, Aubin F

Acta Derm. Venereol.. 2019 08 22;: